Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : 100 symbols : RETA save search
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
Reata Pharmaceuticals 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Reata Pharmaceuticals, Inc. - RETA
Published: 2022-02-18 (Crawled : 03:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.99%
H: 3.66%
C: -0.69%
als ces 100 deadline
REATA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against Reata Pharmaceuticals, Inc. - RETA
Published: 2022-02-16 (Crawled : 04:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.24%
H: 4.36%
C: 3.63%
als ces 100 deadline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.